Advancing Insulin Access: CDSCO Approves New rDNA Origin Injections

As part of its ongoing efforts to improve healthcare accessibility, the CDSCO has granted approval for Insulin Glargine Injection (rDNA Origin) 100 IU/ml, 5ml vial, as of June 30, 2026. This approval is a significant step in addressing the growing burden of diabetes in India, providing patients with a reliable and standardized treatment option. The use of rDNA technology ensures high purity and consistency in the insulin formulation.

Diabetes management requires consistent access to high-quality insulin, and the introduction of new, approved formulations helps stabilize the supply chain for chronic care. By expanding the list of approved insulin products, the CDSCO is helping to mitigate potential shortages and providing healthcare providers with more options to tailor treatment plans for patients. This is particularly vital given the rising prevalence of metabolic disorders across the country.

The approval of Insulin Glargine is part of a wider strategy to enhance the availability of essential medicines. The CDSCO's focus on therapeutic areas like mental health—evidenced by the recent approval of Brexpiprazole—and metabolic health demonstrates a comprehensive approach to public health. These regulatory milestones are essential for building a robust healthcare infrastructure that can support the needs of a diverse and growing population, ensuring that life-saving treatments are both safe and readily available.